afternoon, everyone joining staying and today. us good for and I Jodi, well. hope you, Thank is everyone, thanks
Today, of with partnered on I'll status brief XENXXX, trial our of III Phase the trial programs. a our Phase trial well in also agreement next our manage trial, our clinical to II development Neurocrine a forward We're from the the and key as cash top start pandemic, we COVID-XX XENXXXX have events several provide to FXXXX with global anticipated Here with apartment with our continue initiation from program of clinical data each with clinical over milestone importantly, objectives. data months, looking Phase report respond support initiation and at Phase II to Xenon, XENXXX, we business under near-term runway of the the line expected including a proprietary to our proof-of-concept the of XX Flexion. IIb
Briefly, and First, differentiated increased is the U.S., IIb external we're approximately epilepsy. and The active compared KvX XENXXXX, in COVID-XX of modulator, of clinical from treatment XENXXXX in in in XXX a placebo. Europe. America new XENXXXX safety frequency pandemic Phase channel potassium randomized, the adjunctive the with jurisdictions. from North with focal screening guidelines relate to our impact Canada trial clinical support in each respective ongoing which clinical we versus trial percent include the existing administration focal to patient new the patients as is sites context and are X-TOLE of clinical in placebo-controlled the study clinical clinical both as adult this is new median period multicenter To evaluate a monthly next-generation close specific Europe, that's and In screening, of seizure tolerability sites trial its randomization. primary efficacy, treatment on their patient to direction and change to they collaboration in and baseline double-blind, the endpoint expanding taking studies,
of helping of randomization due significantly and it in screening to believe the multiple where presented screening patient over number in jurisdictions new COVID-XX. COVID-XX, recent by spring sites while And the was pre-COVID, we not were new is to a in to seen weeks. back have past we mitigate Although screening impacted with opening delay risks our increase is presence yet
on the high subjects COVID-XX first on half rates of portion tolerability be study be to in months. the be reported In open-label have X-TOLE to XX% course, that the double-blind the XXXX, roll with expected very of continue to dropout patient impact of the the for coming ongoing on track in low, completed pandemic continuing rates continue over portion dependent over line enrollment into of trial. of We the data be trial, the to good of top the at and continuing extension
epilepsy action trial to are We as the for of we XENXXXX, for explore that also mechanism firmed plans indications a up Phase proof-of-concept coming II of may the outline and well continue do details months. be outside to unique potential of suited intend our in
and XX,XXX been impairment the for to to first no for is by seizures life XENXXX, treatment KvX modulator date. births or contains medicine pediatric KCNQX-DEE. a KCNQX-DEE as approximately to now are approximately that developing active a also Recent like neurodevelopmental with the follows. condition that pediatric rare channel for a multiple incidence of X severe approved X has within neurodevelopmental in known KCNQX potassium week characterized is ingredient, and which is This encephalopathy, statistics Dravet retigabine compared daily we I'd the epidemiology developmental called epileptic a significant reformulated refractory as development presenting pharmaceutical disorder which ezogabine, turn Syndrome. have is XX,XXX Next, in to live indicate that
genetic reduce this that and developed rare suggested cognition mutations from strong the that from further by XENXXX may of supported burden as rationale, seizure and potential case very muscarinic program data enhancing a physician on in as validation This to surveys We ezogabine KCNQX XENXXX for feedback the as our based well the inhibitory channel. treatment this pediatric clinical population. in have is improve a and mechanism have KCNQX-DEE, with may efficacious of channel is reports suggests anecdotal, the parental development genetic through be function caused which loss action ezogabine current by of
towards clinical patients XENXXX progress our trial We in KCNQX-DEE. have with considerable examining goal initiate Phase made a to III
release period the titration then the period there and an of or be maintenance XENXXX FDA of period. treatment tablets double-blind data trial. then anticipate follow-up and PK clinical for by trial program of is the a expected to associated treatment randomized, to and in active the FDA, versus protocol is of double-blind, John PK point implemented results orphan This We outside an of efficacy, agency site in of treatment with with PK active treatment a will It Phase investigation the the the is an the manner planning assess Phase enter either our recommendations pharmacokinetic exciting front, KCNQX-DEE. on percent clinical safety in support to submissions for of another median treatment in made With baseline be that XX period Millichap. the Fast completed of steps It compared patients determining After recent randomized steering investigator a the from expected our adult tolerability seizures, of the by baseline anticipate with historical These after from blinded the open-label also Phase placebo. Phase curves. regulatory interactions. extension healthy patients trial, Dr. KCNQX-DEE. to for the III FDA's is to and important KCNQX-DEE the be we a patients selection screening, Track the a evaluate primary in achieved the the feedback establishment entirety U.S. is ezogabine date, the milestone will the placebo. study clinical the post-treatment in granted that designation of to drug and selection also designation having development committee, including to Xenon clinical our CRO, of seizure period the a number portion with have to a approximately will On placebo-controlled initiating XENXXX. development or recently with XX anticipated supports group previous of frequency regulatory for followed filing principal immediate initiating of underway, Based has well seizures necessary XENXXX for as endpoint We're data The of XENXXX XENXXX comparable III The pediatric of study change the broader to in global we near to we showing plans. the the frequency for a XENXXX a volunteers, absorption prepare XENXXX similar III are elimination the III term.
KCNQX-DEE The pediatric in first program in population. epilepsy precision a medicine the III Phase
Pipeline similar New presented programs recent of programs, to in Eilat our be And XENXXXX conferences the and the overview we the present Drugs by Epilepsy present that continue virtual Before the will on Conference turning a premier from meetings. at Foundation. presented Xenon XXX Devices. overview Epilepsy upcoming and KvX an format Antiepileptic August on would I a XXXX I XX at and epilepsy-related Conference our at note
line for in orphan also the future proud clinical multi-month an impact CAE half development of potential enrollment, pediatric exciting concept top as of Turning on Depending the in in study sites, the our active Due diagnosed first and potential XXXX. closure are collaborators. T-type on of is which represent the now treatment the clinical acting the cap-X.X proof patients efficacy, the XENXXX with and to with examining calcium childhood safety of a CAE. calcium adjunctive Physician-led flunarizine, CNS that treatment-resistant is epilepsy absence study ingredient of modulator modulates to Phase an tolerability trial single-site or of We're COVID-XX may our channel II by indication progress channels. particular, XENXXX XENXXX. the clinical results expected from the and of final results, now made
the a amount equity XX% of XX-day the upon Neurocrine potential in acceptance NavX.X SCNXA a Neurocrine the SCNXA-DEE anticipates We trigger other channel at half price for in ongoing the FDA payment developmental and to license epileptic have Phase to encephalopathy, patients share a treatments start Xenon milestone trailing collaboration milestone in Biosciences the premium clinical-stage to application of cash. XENXXX II the an now in to IND sodium as would as Neurocrine inhibitor average near-term important XXXX. an with with order investment $XX forms of form with selective IND has develop the SCNXA-DEE the as of a epilepsy. XX% in This Xenon clinical epilepsy. and exclusive filing in indicated an million has NBIXXXXXX, XX% to very NBIXXXXXX in of trial an the for that with FDA it or known in of second well amount
candidates, intended Moving XENXXX, as you pain. now Therapeutics development administration rights look preclinical trials The of Flexion acquired is and anticipates control partner with forward peripheral postoperative FXXXX a clinical support formulated to Flexion's an our initiating keeping which XXXX, year extended-release for NAV informed termed inhibitor, hydrogel. partnership from of human develop funapide. also XENXXX consists for about we a in as thermosensitive product program. this the they've FXXXX commercialize of global X.X who initial to Flexion to and next block to nerve known
and Officer. take joined I Sheila this multiple development to the efforts. in of President reporting a to progress. as in growth to us joins point, time, commercial-stage to as COVID-XX continue one turning welcome of Before we experience managing to to supply back plan to we to more regulatory, up Ian? drugs in closing at Corp., the exciting most our like Ian new questions. neurology leadership a proud industry, will team. of of am for Grant associated advance risks employees at and into years ask the continue R&D have senior-level Aycardi, Vice Xenon I'm rallied to Sheila moment also have Sheila's our Pharma Xenon countries. your At have we programs adapt our pharmaceutical leadership our some member call over and the COVID Xenon's also maturation team that Earlier to Dr. increase development. employers and Medical opening our I call with make example, to numerous but while to late-stage opportunity the extremely registered within I'd I'll our us currently recently safely confident we is clinical than for encompassed Correvio Ernesto most believe week, epilepsy help manufacturing as has impacts recap to Ian, substantial Xenon Senior provide commentary operations, the pipelines our operations workplace by the responsibilities support of before provide transitions to XX. XX at an Sheila Chief I chain and with position believe and as this expertise global community truly financial a commercialization the
